Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.0206
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1362449197475.4592
- FreeCF/Share 14.1116
- PFCF 21.7168
- PE 13.1313
- Debt/Assets 0.1976
- DivYield 0.0256
- ROE 0.6695
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | Argus | Buy | Hold | -- | -- | Dec. 8, 2025 |
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
News
Novo CEO Says Wegovy Pill Is Safe and Will Be Widely Available
Published: December 23, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Novo Nordisk President and CEO Mike Doustdar says Christmas has come early with US approval of its Wegovy weight loss pill. He says the company is going "all-in" and they are super excited to be the first to market.
Read More
These 5 Stocks Are Set To Dominate 2026
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Positive
My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Europe, offering geographic diversification. The featured stocks all show significant undervaluation potential based on rather conservative growth scenarios.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
Read More
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
Read More
Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema
Published: December 18, 2025 by: WSJ
Sentiment: Positive
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
Read More
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Published: December 16, 2025 by: CNBC
Sentiment: Positive
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Read More
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Read More
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
Read More
EU drugs regulator backs higher dose of Novo's Wegovy
Published: December 12, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.
Read More
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
Published: December 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
Read More
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
Read More
Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO's two-thirds market cap decline stems from a series of adverse events, some justified but many overdone, with the market ignoring positive developments. Despite recent underperformance versus Eli Lilly, NVO maintains industry-leading margins, robust cash flow, and strong growth prospects, notably with oral GLP-1 candidates.
Read More
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
Published: December 02, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging criticism that Novo's studies had design flaws.
Read More
Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S has acquired Zaltenibart, a Phase 2 MASP-3 inhibitor, for up to $2.1 billion, signaling strong conviction in its long-term potential. NVO shares have declined ~20% since October, now trading at a forward P/E of 13.5x, well below historical and sector averages, presenting a de-risked entry point. Zaltenibart targets rare, high-value indications like PNH and complement-mediated nephropathies, offering multi-billion dollar TAM if Phase 3 data prove compelling.
Read More
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Read More
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
Read More
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
Published: November 26, 2025 by: CNBC
Sentiment: Neutral
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price.
Read More
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.
Read More
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says
Published: November 25, 2025 by: Benzinga
Sentiment: Neutral
Novo Nordisk A/S (NYSE: NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.
Read More
Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill
Published: November 25, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S remains the market leader in obesity and diabetes treatments, despite a recent sharp stock drop and failed Alzheimer's trial. The real growth catalyst for NVO is the upcoming oral semaglutide, which addresses major barriers like affordability and injection aversion. NVO is ahead of Eli Lilly in bringing an oral GLP-1 drug to market, with superior efficacy and a likely 2026 US launch.
Read More
Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention
Published: November 25, 2025 by: Reuters
Sentiment: Neutral
Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs should be tested to prevent the disease in people at risk.
Read More
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
Read More
What's Happening With Novo Nordisk Stock?
Published: November 25, 2025 by: Forbes
Sentiment: Negative
Novo Nordisk's stock has faced pressure following its Ozempic pill's failure in Alzheimer's disease trials, introducing new downside risks for the leader in weight loss medications. While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.
Read More
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.
Published: November 25, 2025 by: Barrons
Sentiment: Positive
Novo Nordisk stock was rebounding in premarket trading Tuesday. It's a tale of two drug trials.
Read More
Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman
Published: November 24, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more.
Read More
Top Stock Movers Now: Alphabet, Tesla, Carvana, Novo Nordisk, and More
Published: November 24, 2025 by: Investopedia
Sentiment: Positive
Major U.S. equities indexes climbed Monday afternoon as tech stocks rallied, and as optimism about a rate cut by the Federal Reserve next month grew. The Dow rose 0.4% and the S&P 500 added 1.3%, while the tech-heavy Nasdaq surged over 2%.
Read More
Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.
Published: November 24, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406